You are currently viewing a new version of our website. To view the old version click .

Journal of Personalized Medicine, Volume 9, Issue 3

September 2019 - 13 articles

Cover Story: Pharmacogenetics and biomarkers are becoming normalised as important technologies to improve drug efficacy rates, reduce the incidence of adverse drug reactions, and make informed choices for targeted therapies. However, their wider clinical implementation has been limited by a lack of robust evidence. Suitable evidence is required before a biomarker’s clinical use, and also before its use in a clinical trial. We have undertaken a review of five pharmacogenetic biomarker-guided randomised controlled trials (RCTs) and evaluated the evidence used by these trials to justify biomarker inclusion. Very different levels of evidence were provided by the trials. We used these observations to write recommendations for future justifications of biomarker use in RCTs and encourage regulatory authorities to write clear guidelines. View this paper.
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (13)

  • Perspective
  • Open Access
10 Citations
6,824 Views
10 Pages

12 September 2019

Cancer is a leading cause of death worldwide and therefore one of the most important public health concerns. In this contribution, we discuss recent key enabling technological innovations (and their challenges), including biomarker-based technologies...

  • Review
  • Open Access
18 Citations
7,786 Views
17 Pages

Precision Oncology—The Quest for Evidence

  • Theodoros G. Soldatos,
  • Sajo Kaduthanam and
  • David B. Jackson

5 September 2019

The molecular characterization of patient tumors provides a rational and highly promising approach for guiding oncologists in treatment decision-making. Notwithstanding, genomic medicine still remains in its infancy, with innovators and early adopter...

  • Review
  • Open Access
3 Citations
7,904 Views
19 Pages

Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials

  • Danielle Johnson,
  • Dyfrig Hughes,
  • Munir Pirmohamed and
  • Andrea Jorgensen

1 September 2019

Pharmacogenetics and biomarkers are becoming normalised as important technologies to improve drug efficacy rates, reduce the incidence of adverse drug reactions, and make informed choices for targeted therapies. However, their wider clinical implemen...

  • Case Report
  • Open Access
10 Citations
7,179 Views
16 Pages

Case of Early-Onset Parkinson’s Disease in a Heterozygous Mutation Carrier of the ATP7B Gene

  • Ekaterina Y. Ilyechova,
  • Irina V. Miliukhina,
  • Marina N. Karpenko,
  • Iurii A. Orlov,
  • Ludmila V. Puchkova and
  • Sergey A. Samsonov

17 August 2019

In this paper, we report a clinically proven case of Parkinson’s disease (PD) with early onset in a patient who is a heterozygous mutation carrier of ATP7B (the Wilson’s disease gene). The patient was observed from 2011 to 2018 in the Cen...

  • Review
  • Open Access
93 Citations
16,881 Views
25 Pages

Pharmacogenomics can enhance patient care by enabling treatments tailored to genetic make-up and lowering risk of serious adverse events. As of June 2019, there are 132 pharmacogenomic dosing guidelines for 99 drugs and pharmacogenomic information is...

  • Editorial
  • Open Access
17 Citations
7,315 Views
6 Pages

This article aims to discuss the recent development of integrated point-of-care spectroscopic-based technologies that are paving the way for the next generation of diagnostic monitoring technologies in personalized medicine. Focusing on the nuclear m...

  • Article
  • Open Access
6 Citations
6,701 Views
18 Pages

For more than a decade, genome-wide association studies have been making steady progress in discovering the causal gene variants that contribute to late-onset human diseases. Polygenic late-onset diseases in an aging population display a risk allele...

  • Review
  • Open Access
8 Citations
6,839 Views
9 Pages

Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma

  • Matthew Loft,
  • Belinda Lee,
  • Jeanne Tie and
  • Peter Gibbs

Pancreatic adenocarcinoma remains one of the most aggressive cancers with an ongoing dismal survival rate despite some recent advances in treatment options. This is largely due to the typically late presentation and limited effective therapeutic opti...

  • Article
  • Open Access
32 Citations
10,622 Views
9 Pages

Determination of Risk Factors for Venous Thromboembolism by an Adapted Caprini Scoring System in Surgical Patients

  • Bui My Hanh,
  • Le Quang Cuong,
  • Nguyen Truong Son,
  • Duong Tuan Duc,
  • Tran Tien Hung,
  • Duong Duc Hung,
  • Tran Binh Giang,
  • Nguyen Hoang Hiep,
  • Hoang Thi Hong Xuyen and
  • Nguyen Thi Nga
  • + 1 author

Venous thromboembolism (VTE) is a frequent preventable complication among surgical patients. Precise risk assessment is a necessary step for providing appropriate thromboprophylaxis and reducing mortality as well as morbidity caused by VTE. We carrie...

  • Review
  • Open Access
55 Citations
12,416 Views
21 Pages

Blockchains for Secure Digitized Medicine

  • Khaled Shuaib,
  • Heba Saleous,
  • Karim Shuaib and
  • Nazar Zaki

Blockchain as an emerging technology has been gaining in popularity, with more possible applications to utilize the technology in the near future. With the offer of a decentralized, distributed environment without the need for a third trusted party (...

of 2

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
J. Pers. Med. - ISSN 2075-4426